Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026)

Anika Therapeutics (ANIK) has reported Change in Account Payables for 17 consecutive years, with -$575000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Account Payables rose 48.34% year-over-year to -$575000.0 in Q2 2026; TTM through Jun 2026 was $1.3 million, a 131.01% increase from a year earlier, with the FY2025 full-year figure at $42000.0, up 101.68% from the prior year.
• Change in Account Payables was -$575000.0 for Q2 2026 at Anika Therapeutics, down from $745000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $1.4 million in Q4 2022 and troughed at -$2.9 million in Q3 2024.
• A 5-year average of -$18888.9 and a median of $97500.0 in 2024 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables tumbled 911.72% in 2024 and jumped 1485.11% in 2026, its largest moves.
• Over 5 years, Change in Account Payables stood at $1.4 million in 2022, then retreated by 8.66% to $1.3 million in 2023, then plunged by 109.25% to -$121000.0 in 2024, then surged by 824.79% to $877000.0 in 2025, then tumbled by 165.56% to -$575000.0 in 2026.
• The last three Change in Account Payables figures came in at -$575000.0 (Q2 2026), $745000.0 (Q1 2026), and $877000.0 (Q4 2025), per Business Quant data.